These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3718560)

  • 1. Treatment of AL amyloidosis with melphalan, prednisone, and colchicine.
    Benson MD
    Arthritis Rheum; 1986 May; 29(5):683-7. PubMed ID: 3718560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of primary amyloidosis with melphalan and prednisone.
    Schwartz RS; Cohen JR; Schrier SL
    Arch Intern Med; 1979 Oct; 139(10):1144-7. PubMed ID: 485747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine.
    Kyle RA; Greipp PR; Garton JP; Gertz MA
    Am J Med; 1985 Dec; 79(6):708-16. PubMed ID: 3934968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.
    Kyle RA; Gertz MA; Greipp PR; Witzig TE; Lust JA; Lacy MQ; Therneau TM
    N Engl J Med; 1997 Apr; 336(17):1202-7. PubMed ID: 9110907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.
    Skinner M; Anderson J; Simms R; Falk R; Wang M; Libbey C; Jones LA; Cohen AS
    Am J Med; 1996 Mar; 100(3):290-8. PubMed ID: 8629674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary amyloidosis with unusual bone involvement: reversibility with melphalan, prednisone, and colchicine.
    Schattner A; Varon D; Green L; Hurwitz N; Bentwich Z
    Am J Med; 1989 Mar; 86(3):347-8. PubMed ID: 2919619
    [No Abstract]   [Full Text] [Related]  

  • 7. AL amyloidosis: therapeutic response in two patients with renal involvement.
    Goddard IR; Jackson R; Jones JM
    Nephrol Dial Transplant; 1991; 6(8):592-4. PubMed ID: 1956560
    [No Abstract]   [Full Text] [Related]  

  • 8. Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone.
    Kyle RA; Wagoner RD; Holley KE
    Arch Intern Med; 1982 Aug; 142(8):1445-7. PubMed ID: 7103624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy options in systemic AL-amyloidosis with renal involvement].
    Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The successful treatment of primary amyloidosis with intermittent chemotherapy.
    Bradstock K; Clancy R; Uther J; Basten A; Richards J
    Aust N Z J Med; 1978 Apr; 8(2):176-9. PubMed ID: 277166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo.
    Kyle RA; Greipp PR
    Blood; 1978 Oct; 52(4):818-27. PubMed ID: 356916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Amyloidosis in a mixed pattern. Sensitivity to colchicine and melphalan].
    Frustaci A; Gentiloni N; Feoli F
    Minerva Med; 1981 Apr; 72(15):957-60. PubMed ID: 6784038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome.
    Cohen HJ; Lessin LS; Hallal J; Burkholder P
    Ann Intern Med; 1975 Apr; 82(4):466-73. PubMed ID: 1119764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloidosis.
    Cohen AS; Jones LA
    Curr Opin Rheumatol; 1991 Feb; 3(1):125-38. PubMed ID: 2043438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An unusual case of primary systemic amyloidosis.
    Ambrosone L; Mansi L; Salvatore T; Marino F; Orabona P; Rambaldi A; Rambaldi PF; Rambaldi M
    J Eur Acad Dermatol Venereol; 1998 Jan; 10(1):53-7. PubMed ID: 9552758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current management of amyloidosis].
    Hirayama C
    Nihon Rinsho; 1991 Apr; 49(4):956-60. PubMed ID: 2072560
    [No Abstract]   [Full Text] [Related]  

  • 17. Amyloidosis of immunoglobulin origin: useful treatment?
    Brown MP; Walls RS
    Med J Aust; 1990 Jan; 152(2):95-7. PubMed ID: 2104951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response rates and survival in primary systemic amyloidosis.
    Gertz MA; Kyle RA; Greipp PR
    Blood; 1991 Jan; 77(2):257-62. PubMed ID: 1985692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Falk RH; Berk JL; Dember LM; Finn KT; Skinner M
    Br J Haematol; 2002 Jun; 117(4):886-9. PubMed ID: 12060126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary cardiac amyloidosis with 20-year survival.
    Fealey ME; Edwards WD; Grogan M; Dispenzieri A
    Cardiovasc Pathol; 2006; 15(6):331-5. PubMed ID: 17113011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.